Zika Virus RNA Persistence in Pregnant Women and Congenitally Exposed Infants in Puerto Rico (ZIRP)

ICR 201706-0920-003

OMB: 0920-1189

Federal Form Document

Forms and Documents
Document
Name
Status
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Supporting Statement B
2017-07-07
Supporting Statement A
2017-07-07
Supplementary Document
2017-07-07
Supplementary Document
2017-07-07
Supplementary Document
2017-07-07
Supplementary Document
2017-07-07
Supplementary Document
2017-07-07
Supplementary Document
2017-07-07
Supplementary Document
2017-07-07
ICR Details
0920-1189 201706-0920-003
Historical Active
HHS/CDC 0920-17NF
Zika Virus RNA Persistence in Pregnant Women and Congenitally Exposed Infants in Puerto Rico (ZIRP)
New collection (Request for a new OMB Control Number)   No
Emergency 07/10/2017
Approved without change 07/10/2017
Retrieve Notice of Action (NOA) 07/10/2017
As the information collection is scheduled to last for 15 months, CDC will submit a full Information Collection Request within 3 months after getting emergency approval
  Inventory as of this Action Requested Previously Approved
10/31/2017 6 Months From Approved
6,000 0 0
785 0 0
0 0 0

The Emergency ZIRP study aims to determine the prevalence and duration of ZIKV RNA persistence in pregnant women infected with ZIKV and their congenitally exposed infants. Information from the ZIRP Puerto Rico study will provide the data needed to establish ZIKV testing guidance for pregnant women and congenitally exposed infants, and will also provide information to assess the association between persistent ZIKV RNA in pregnant women or infants and adverse outcomes.
Currently, the Centers for Disease Control and Prevention (CDC) and the PRDH recommend that all pregnant women living in areas with active ZIKV transmission such as Puerto Rico, be tested for ZIKV. Limited data from human studies also suggest that pregnant women have persistent detection of ZIKV RNA in serum. Even less is known about persistent detection of ZIKV RNA in infants. One case study reported persistent ZIKV RNA detection in a male child born in Brazil at 40 weeks gestation with brain abnormalities. The increasing number of cases and stage of the outbreak in Puerto Rico provides an opportunity to collect actionable information on a shorter timeframe than is possible elsewhere. This study is expected to provide critical scientific information to help the United States prepare for the unprecedented challenges posed by Zika and possible clinical guidelines related to ZIKV RNA testing. Because information collection is scheduled to last for 15 months, CDC will submit a full Information Collection Request within 3 months after getting emergency approval.

US Code: 42 USC 241 Name of Law: U.S. PHSA
  
None

Not associated with rulemaking

  82 FR 18462 04/19/2017
No

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 6,000 0 0 6,000 0 0
Annual Time Burden (Hours) 785 0 0 785 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
Submission of 0920-17NF - Zika Virus RNA Persistence in Pregnant Women and Congenitally Exposed Infants in Puerto Rico (ZIRP) is a New Emergency Clearance Request.

$1,333,820
Yes Part B of Supporting Statement
No
No
No
No
Uncollected
Jeffrey Zirger 404 639-7118 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
07/10/2017


© 2024 OMB.report | Privacy Policy